Jun 07, 2026, 17:30 ET CagriSema, a once-weekly investigational treatment that combines a novel amylin analog with a GLP-1 receptor agonist (RA), achieved significant reductions in HbA 1c and bodyweight versus comparators across three phase 3 trials in adults with type 2 diabetes (T2D) 1-3 Data from the REIMAGINE clinical development program, a series of phase 3 trials evaluating once-weekly CagriSema in adults with T2D across various stages of their disease, were presented at an ADA symposium 1-3 Novo Nordisk continues to demonstrate pioneering leadership and scientific innovation through advancing diabetes research PLAINSBORO, N.J
The challenge with taking NAD+ orally has always been bioavailability
The most common side effects are mild and transient: injection site reaction, brief flushing, occasional headache, vivid dreams, and mild edema
MicroRNA modulators of epigenetic regulation, the tumor microenvironment and the immune system in lung cancer
This effect is likely due to the drugs ability to reduce brain inflammation, improve insulin resistance, and lower the impact of Alzheimers biomarkers
How Acetaminophen Is Metabolized: Safe vs
